



Attorney Docket No.: 6034.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 09/891,691 Group Art Unit: 1617

Filed: June 26, 2001 Examiner: Shaojia A. Jiang

Confirmation No.: 1796

For: Use of Potassium Channel Agonists for Reducing Fat Food Consumption

RECEIVED
FEB 27 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231
Box RCE

Sir:

I hereby certify that the attached correspondence comprising:

1. Request for Continued Examination Transmittal

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231
Box RCE

on February 13, 2003.

Cheryl H. Agris

(name of person mailing paper)

Cheryl H. Agris

(signature of person mailing paper)



Attorney Docket No.: 6034.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 09/891,691

Group Art Unit: 1617

Filed: June 26, 2001

Examiner: Shaojia A. Jiang

Confirmation No.: 1796

For: Use of Potassium Channel Agonists for Reducing Fat Food Consumption

RCE/1600 #
PATENT
RECEIVED
FEB 27 2003
TECH CENTER 1600/2900
#14
AKO
3-603

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents
Box RCE
Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above identified application.

1. Submission required under 37 C.F. R. § 1.114

a. ☒ Previously submitted

- i. ☒ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on January 13, 2003
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

b. ☐ Enclosed

- i. ☐ Amendment / Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other

2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17 (i) required)

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account 14-1447.

02/25/2003 SSITHIB1 00000143 141447 09891691

01 FC:1801 750.00 CH

02/25/2003 SSITHIB1 00000143 141447 09891691
02 FC:1253 530.00 CH

4. Fees-The RCE fee under 37 C.F.R. §1.17 (e) is required by 37 C.F.R. §1.114 when the RCE is filed.


a. ☒ The Director is hereby authorized to charge the following fees, any other payments or credit any overpayments, to Deposit **Account No. 14-1447**.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e) (\$750)
- ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) (\$520)
- iii. ☐ Other

Date:

2/13/03

Respectfully submitted,



Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540